• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Oncology in Advance – May 15th, 2007 – reporting from: American Association for Cancer Research, April 14-18, 2007, Los Angeles, CA

  • in ASCO · Oncology
  • — 16 May, 2007
Alberto Sobrero
Alberto Sobrero

Cetuximab With Irinotecan: Phase III Study Shows Benefit in Patients with Oxaliplatin-Refractory Colorectal Cancer

REFERENCE: ABSTRACT LB-2; AACR 2007, Los Angeles, Plenary Session
ALBERTO SOBRERO, Ospedale San Martino, Genoa
Cetuximab could become a mainstay of treatment for colorectal cancer along with fluorouracil, oxaliplatin, irinotecan, and bevacizumab, according to findings from the EPIC study presented at the AACR meeting in Los Angeles. 1,300 patients who had failed previous therapy with oxaliplatin were randomly assigned to receive irinotecan with or without cetuximab. The results point to a benefit of adding the molecular therapy, even though the effect was diluted because the protocol permitted crossover. Alberto Sobrero presented the data in Los Angeles, where he talked about it with Peter Goodwin.

Derek Jonker
Derek Jonker

Cetuximab Monotherapy Benefits Patients With Refractory Metastatic Colorectal Cancer

REFERENCE: ABSTRACT LB-1, AACR 2007, Los Angeles: Plenary Session
DEREK JONKER, University of Ottawa
The molecularly targeted drug cetuximab has now proved capable of extending life when used as monotherapy among patients with refractory colorectal cancer. The CO17 phase III randomized trial of cetuximab versus best supportive care shows improvements in overall survival, progression-free survival, response rate, safety, and quality of life in a study with almost 600 patients who had metastatic colorectal cancer that had progressed despite all previous therapies. Derek Jonker told Karen Regester about their results with cetuximab monotherapy, which followed earlier promising work using the agent in combination with cytotoxic therapy.

Richard Goldberg
Richard Goldberg

Cetuximab’s Role in Colorectal Cancer

REFERENCE: ABSTRACT LB-1 and LB-2; AACR 2007, Los Angeles Plenary Session, Monday 16th April, 2006
RICHARD GOLDBERG, University of North Carolina, Chapel Hill
Following the presentations from David Jonker and Alberto Sobrero at the AACR conference in Los Angeles, Richard Goldberg assessed the role of cetuximab in the treatment of metastatic, refractory colorectal cancer. He discussed the latest findings and his conclusions about their clinical implications with Peter Goodwin.

To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.

You may also like...

  • Audio Journal of Oncology in Advance – November 1st, 2006 Audio Journal of Oncology in Advance – November 1st, 2006 1 Nov, 2006
  • Ian Kunkler Stage I to III breast cancer: radiation therapy to chest lymph nodes extends life 26 Oct, 2013
  • Mario Sznol PD 1 inhibitor nivolumab shows promising activity in metastatic melanoma 21 Sep, 2013

2 Comments

  1. wang xiaodong says:
    May 29, 2007 at 2:34 am

    I need the audio on breast cancer.thanks

  2. admin says:
    June 2, 2007 at 10:53 am

    To listen to the ASCO Audio Journal in Advance audio please go to http://www.asco.org/portal/site/ASCO/menuitem.5d1b4bae73a9104ce277e89a320041a0/?vgnextoid=ad14caad9626b010VgnVCM100000f2730ad1RCRD

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Audio Journal of Cardiovascular Medicine: Reduced Mortality and Repeat MI with Enoxaparin for Patients with ST Elevation Myocardial Infarction
  • Next story Non-Perfect HIV Vaccine Could Still Have Major Benefits
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with…
    • Two Drug Combination Doubled Kidney Cancer…
  • Home
  • Oncology
  • ASCO
  • Audio Journal of Oncology in Advance – May 15th, 2007 – reporting from: American Association for Cancer Research, April 14-18, 2007, Los Angeles, CA

© COPYRIGHT 2020 AUDIOMEDICA.COM.